US3894920A
(en)
|
1971-12-21 |
1975-07-15 |
Sagami Chem Res |
Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
|
US4016287A
(en)
|
1972-07-17 |
1977-04-05 |
Boehringer Ingelheim Gmbh |
Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
|
BR8807740A
(en)
|
1988-07-25 |
1990-10-16 |
V Kurgansky Nauchny Ts Vosstan |
TRACTION APPLIANCE FOR HAND PLASTIC RECONSTRUCTION
|
TW219933B
(en)
|
1990-02-26 |
1994-02-01 |
Lilly Co Eli |
|
US5405613A
(en)
|
1991-12-11 |
1995-04-11 |
Creative Nutrition Canada Corp. |
Vitamin/mineral composition
|
TW352384B
(en)
|
1992-03-24 |
1999-02-11 |
Hoechst Ag |
Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
|
DE4219158A1
(en)
|
1992-06-11 |
1993-12-16 |
Thomae Gmbh Dr K |
Biphenyl derivatives, pharmaceutical compositions containing them and processes for their preparation
|
ATE149485T1
(en)
|
1993-11-02 |
1997-03-15 |
Hoechst Ag |
SUBSTITUTED HETEROCYCLIC CARBOXYLIC AMIDE ESTERS, THEIR PREPARATION AND THEIR USE AS MEDICINAL PRODUCTS
|
ES2101421T3
(en)
|
1993-11-02 |
1997-07-01 |
Hoechst Ag |
SUBSTITUTED HETERO-CYCLIC CARBOXYLIC ACID AMIDES, THEIR PREPARATION AND THEIR USE AS MEDICINES.
|
TW406076B
(en)
|
1993-12-30 |
2000-09-21 |
Hoechst Ag |
Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
|
DE4410480A1
(en)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridine-2-carboxylic acid ester amides and their pyridine N-oxides, processes for their preparation and their use as medicaments
|
DE4410423A1
(en)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carboxamides and their pyridine N-oxides, processes for their preparation and their use as medicaments
|
IL135495A
(en)
|
1995-09-28 |
2002-12-01 |
Hoechst Ag |
Intermediate compounds for the preparation of substituted quinoline-2-carboxylic acid amides
|
JPH09221476A
(en)
|
1995-12-15 |
1997-08-26 |
Otsuka Pharmaceut Co Ltd |
Medicinal composition
|
EP0900202A1
(en)
|
1996-04-30 |
1999-03-10 |
Hoechst Aktiengesellschaft |
3-alkoxypyridine-2-carboxylic acid amide esters, their preparation and their use as drugs
|
DE19620041A1
(en)
|
1996-05-17 |
1998-01-29 |
Merck Patent Gmbh |
Adhesion receptor antagonists
|
DE19650215A1
(en)
|
1996-12-04 |
1998-06-10 |
Hoechst Ag |
3-hydroxypyridine-2-carboxylic acid amide esters, their preparation and their use as medicaments
|
EP1024134A4
(en)
|
1997-10-09 |
2003-05-14 |
Ono Pharmaceutical Co |
Aminobutanoic acid derivatives
|
DE19746287A1
(en)
|
1997-10-20 |
1999-04-22 |
Hoechst Marion Roussel De Gmbh |
Substituted isoquinoline-2-carboxylic acid amides, their preparation and their use as medicaments
|
JP4495339B2
(en)
|
1998-03-23 |
2010-07-07 |
アベンティス・ファーマスーティカルズ・インコーポレイテツド |
Piperidinyl and N-amidinopiperidinyl derivatives
|
ATE334993T1
(en)
|
1998-08-27 |
2006-08-15 |
Teva Pharma |
HYDRATE FORMS OF THE SODIUM SALT OF ALENDRONATE, METHOD FOR THE PRODUCTION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME
|
EP1133459B1
(en)
|
1998-11-27 |
2006-01-11 |
Teva Pharmaceutical Industries Ltd. |
Sertraline hydrochloride form v
|
US6500987B1
(en)
|
1998-11-27 |
2002-12-31 |
Teva Pharmaceutical Industries Ltd. |
Sertraline hydrochloride polymorphs
|
US6159379A
(en)
|
1999-05-04 |
2000-12-12 |
Baker Hughes Incorporated |
Organic ammonium salts for the removal of water soluble organics in produced water
|
JP2001048786A
(en)
|
1999-08-05 |
2001-02-20 |
Yamanouchi Pharmaceut Co Ltd |
Tricyclic heteroaryl derivative
|
MXPA02001369A
(en)
|
1999-08-11 |
2005-08-26 |
Teva Pharma |
Torsemide polymorphs.
|
PL355805A1
(en)
|
1999-11-17 |
2004-05-17 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic form of atorvastatin calcium
|
CN1434702A
(en)
|
1999-12-14 |
2003-08-06 |
拜奥盖尔药厂有限公司 |
Novel forms of pravastatin sodium
|
RU2002116232A
(en)
|
1999-12-16 |
2004-01-10 |
Тева Фамэситикл Индастрис Лтд. (Il) |
The method of obtaining polymorphic modifications of clarithromycin and a new polymorphic modification IV
|
JP2003517011A
(en)
|
1999-12-16 |
2003-05-20 |
テバ ファーマシューティカル インダストリーズ リミティド |
A new process and new crystal form of leflunomide
|
HUP0204010A3
(en)
|
1999-12-21 |
2006-02-28 |
Teva Pharma |
Novel sertraline hydrochloride polymorphs, processes for preparing them, compositions containing them and their use
|
NZ519984A
(en)
*
|
2000-01-07 |
2004-03-26 |
Transform Pharmaceuticals Inc |
High-throughput formation, identification, and analysis of diverse solid-forms
|
DK1280535T3
(en)
|
2000-01-11 |
2005-04-04 |
Teva Pharma |
Processes for the preparation of clarithromycin polymorphs
|
US6589758B1
(en)
|
2000-05-19 |
2003-07-08 |
Amgen Inc. |
Crystal of a kinase-ligand complex and methods of use
|
SK2242003A3
(en)
|
2000-07-27 |
2003-10-07 |
Teva Pharma |
Crystalline and pure modafinil, and process of preparing the same
|
WO2002045658A2
(en)
|
2000-10-19 |
2002-06-13 |
Teva Pharmaceutical Industries Ltd. |
Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
|
US20020183553A1
(en)
|
2000-10-19 |
2002-12-05 |
Ben-Zion Dolitzky |
Crystalline venlafaxine base and novel polymorphs of venlafaxine hydrochloride, processes for preparing thereof
|
AU2002230935A1
(en)
|
2000-10-30 |
2002-05-15 |
Teva Pharmaceutical Industries Ltd. |
Novel crystal and solvate forms of ondansetron hydrochloride and processes for their preparation
|
US6605636B2
(en)
|
2000-11-03 |
2003-08-12 |
Teva Pharmaceutical Industries Ltd. |
Atorvastatin hemi-calcium form VII
|
US7501450B2
(en)
|
2000-11-30 |
2009-03-10 |
Teva Pharaceutical Industries Ltd. |
Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
|
IL156055A0
(en)
|
2000-11-30 |
2003-12-23 |
Teva Pharma |
Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
|
CA2437402A1
(en)
|
2001-02-12 |
2002-08-22 |
Teva Pharmaceutical Industries, Ltd. |
New crystal forms of oxcarbazepine and processes for their preparation
|
US6855510B2
(en)
|
2001-03-20 |
2005-02-15 |
Dana Farber Cancer Institute, Inc. |
Pharmaceuticals and methods for treating hypoxia and screening methods therefor
|
US6849718B2
(en)
|
2001-03-20 |
2005-02-01 |
Dana Farber Cancer Institute, Inc. |
Muteins of hypoxia inducible factor alpha and methods of use thereof
|
US20040146964A1
(en)
|
2001-03-21 |
2004-07-29 |
Maxwell Patrick Henry |
Assays, methods and means
|
EP1392303A4
(en)
|
2001-04-09 |
2005-01-26 |
Teva Pharma |
Polymorphs of fexofenadine hydrochloride
|
SE0101327D0
(en)
|
2001-04-12 |
2001-04-12 |
Astrazeneca Ab |
New crystalline forms
|
CZ200471A3
(en)
|
2001-08-01 |
2004-11-10 |
Biogal Gyogyszergyar Rt |
Purification process of N-[3-(3-cyanopyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-N-ethyl-acetamide (zaleplon) and zaleplon crystalline forms prepared in such a manner
|
EP1436295A4
(en)
|
2001-09-07 |
2007-07-11 |
Teva Pharma |
Crystalline forms of valacyclovir hydrochloride
|
DE60215213T3
(en)
|
2001-10-03 |
2010-07-01 |
Teva Pharmaceutical Industries Ltd. |
PREPARATION OF LEVOFLOXACIN HEMIHYDRATE
|
US6566088B1
(en)
|
2001-10-04 |
2003-05-20 |
Board Of Regents, The University Of Texas System |
Prolyl-4-hydroxylases
|
GB0124941D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
WO2003039482A2
(en)
|
2001-11-08 |
2003-05-15 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of fexofenadine base
|
HUP0501067A2
(en)
|
2001-11-14 |
2006-02-28 |
Teva Pharma |
Amorphous and crystalline forms of losartan potassium and process for their preparation
|
US6734314B2
(en)
|
2001-12-04 |
2004-05-11 |
Biogal Gyogyszergyar Rt. |
Preparation of orlistat and orlistat crystalline forms
|
DK2289531T3
(en)
|
2001-12-06 |
2018-10-01 |
Fibrogen Inc |
Medications for the treatment or prevention of anemia
|
CA2470479A1
(en)
|
2001-12-18 |
2003-06-26 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of clopidogrel hydrogensulfate
|
CA2460970C
(en)
|
2001-12-28 |
2005-10-18 |
Biogal Gyogyszergyar Rt |
Processes for preparing crystalline and amorphous mupirocin calcium
|
JP2005515226A
(en)
|
2002-01-15 |
2005-05-26 |
テバ ファーマシューティカル インダストリーズ リミティド |
Crystalline solids of carvedilol and methods for preparing them
|
ES2241507T1
(en)
|
2002-02-15 |
2005-11-01 |
Teva Pharmaceutical Industries Ltd. |
NEW FORMS OF CRYSTAL OF SEMICALCID ATORVASTATIN AND PROCEDURES FOR THEIR PREPARATION, AS WELL AS NEW PROCEDURES FOR THE PREPARATION OF FORMS I, VIII AND IX OF SEMICALCICA ATORVASTATIN.
|
US20030216376A1
(en)
|
2002-03-20 |
2003-11-20 |
Revital Lifshitz-Liron |
Crystalline forms of quetiapine hemifumarate
|
MXPA04009384A
(en)
|
2002-03-27 |
2005-01-25 |
Teva Pharma |
Lansoprazole polymorphs and processes for preparation thereof.
|
US20030195170A1
(en)
|
2002-04-11 |
2003-10-16 |
Judith Aronhime |
Novel polymorphs and pseudopolymorphs of risedronate sodium
|
EP1499581A1
(en)
|
2002-04-29 |
2005-01-26 |
Teva Pharmaceutical Industries Ltd. |
Process for preparation of polymorphic form ii of sertraline hydrochloride, pharmaceutical formulations and methods of administration thereof
|
EP1465887A1
(en)
|
2002-04-30 |
2004-10-13 |
Teva Gyogyszergyar Reszvenytarsasag |
Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
|
CN1665504A
(en)
|
2002-05-10 |
2005-09-07 |
特瓦制药工业有限公司 |
Novel crystalline forms of gatifloxacin
|
JP2005532356A
(en)
|
2002-06-10 |
2005-10-27 |
テバ ファーマシューティカル インダストリーズ リミティド |
Polymorph XVI of fexofenadine hydrochloride
|
JP2005532364A
(en)
|
2002-06-14 |
2005-10-27 |
テバ ファーマシューティカル インダストリーズ リミティド |
A novel crystalline form of gatifloxacin
|
WO2004009532A1
(en)
|
2002-07-18 |
2004-01-29 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of nateglinide
|
US7534913B2
(en)
|
2002-07-18 |
2009-05-19 |
Teva Pharmaceutica Industries Ltd. |
Crystalline form of nateglinide
|
US20040022764A1
(en)
*
|
2002-07-31 |
2004-02-05 |
Hanan Polansky |
Inhibition of microcompetition with a foreign polynucleotide as treatment of chronic disease
|
AU2003258109A1
(en)
|
2002-08-06 |
2004-02-23 |
Teva Pharmaceutical Industries Ltd. |
Novel crystalline forms of gatifloxacin
|
AU2003268213A1
(en)
|
2002-08-26 |
2004-03-11 |
Teva Pharmaceutical Industries Ltd. |
Crystalline solid famciclovir forms i, ii, iii and preparation thereof
|
US20050043329A1
(en)
|
2002-09-06 |
2005-02-24 |
Shlomit Wizel |
Crystalline forms of valacyclovir hydrochloride
|
EP1572643A2
(en)
|
2002-11-28 |
2005-09-14 |
Teva Pharmaceutical Industries Ltd. |
Crystalline form f of atorvastatin hemi-calcium salt
|
US7618940B2
(en)
|
2002-12-06 |
2009-11-17 |
Fibrogen, Inc. |
Fat regulation
|
US8124582B2
(en)
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
EP1485097A1
(en)
|
2002-12-12 |
2004-12-15 |
Teva Pharmaceutical Industries Limited |
Crystalline forms of gatifloxacin and processes for preparation
|
EP1575962A1
(en)
|
2002-12-24 |
2005-09-21 |
Teva Pharmaceutical Industries Limited |
Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
|
PL1507531T3
(en)
|
2003-03-12 |
2007-06-29 |
Teva Pharma |
Stable pharmaceutical compositions of desloratadine
|
EP1601667A2
(en)
|
2003-03-12 |
2005-12-07 |
Teva Pharmaceutical Industries Limited |
Crystalline and amorphous solids of pantoprazole and processes for their preparation
|
WO2004083192A1
(en)
|
2003-03-17 |
2004-09-30 |
Teva Pharmaceutical Industries Ltd. |
Polymorphis of valsartan
|
US7452991B2
(en)
|
2003-05-15 |
2008-11-18 |
Teva Gyógyszergyár Zártkörüen Müködö Részvénytársaság |
Aztreonam β polymorph with very low residual solvent content
|
TW200510414A
(en)
|
2003-06-02 |
2005-03-16 |
Teva Pharma |
Novel crystalline forms of valacyclovir hydrochloride
|
CA2528100A1
(en)
|
2003-06-03 |
2005-04-21 |
Teva Pharmaceutical Industries Ltd |
Polymorphic forms of ziprasidone hcl and processes for their preparation
|
CN103145616B
(en)
|
2003-06-06 |
2015-09-30 |
菲布罗根有限公司 |
Nitrogen-containing heteroaryl compounds and the purposes in increase endogenous erythropoietin thereof
|
PT1638937E
(en)
|
2003-06-18 |
2009-01-27 |
Teva Pharma |
Fluvastatin sodium crystal form xiv, processes for preparing it, compositions containing it and methods of using it
|
US7368468B2
(en)
|
2003-06-18 |
2008-05-06 |
Teva Pharmaceutical Industries Ltd. |
Fluvastatin sodium crystal forms XIV, LXXIII, LXXIX, LXXX and LXXXVII, processes for preparing them, compositions containing them and methods of using them
|
GB0314129D0
(en)
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
EP1567533B1
(en)
|
2003-07-03 |
2009-03-11 |
Teva Pharmaceutical Industries Ltd. |
Zoledronic acid crystal forms, zoledronate sodium salt crystal forms, amorphous zoledronate sodium salt, and processes for their preparation
|
TW200526596A
(en)
|
2003-11-24 |
2005-08-16 |
Teva Pharma |
Crystalline ammonium salts of rosuvastatin
|
EP1594493A2
(en)
|
2003-12-16 |
2005-11-16 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of tegaserod base and salts thereof
|
WO2005058835A2
(en)
|
2003-12-16 |
2005-06-30 |
Teva Pharmaceutical Industries Ltd. |
Methods of preparing aripiprazole crystalline forms
|
EP1592688A2
(en)
|
2003-12-18 |
2005-11-09 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic form b2 of ziprasidone base
|
EP1709002A2
(en)
|
2004-01-30 |
2006-10-11 |
Teva Pharmaceutical Industries Ltd. |
Montelukast sodium polymorphs
|
US20050187243A1
(en)
|
2004-01-30 |
2005-08-25 |
Valerie Niddam-Hildesheim |
Montelukast free acid polymorphs
|
WO2005077941A2
(en)
|
2004-02-11 |
2005-08-25 |
Teva Pharmaceutical Industries Ltd. |
Candesartan cilexetil polymorphs
|
WO2005108370A1
(en)
|
2004-04-16 |
2005-11-17 |
Ajinomoto Co., Inc. |
Benzene compounds
|
US20050256163A1
(en)
|
2004-04-26 |
2005-11-17 |
Ilan Kor |
Crystalline forms of fexofenadine hydrochloride and processes for their preparation
|
MXPA06012793A
(en)
|
2004-05-07 |
2007-07-18 |
Teva Pharma |
Polymorphic forms of nateglinide.
|
EP1747223A1
(en)
|
2004-05-18 |
2007-01-31 |
Teva Pharmaceutical Industries Ltd. |
Drying process for preparing crystalline solid famciclovir
|
US20050272821A1
(en)
|
2004-05-20 |
2005-12-08 |
Valeriano Merli |
Levalbuterol hydrochloride Polymorph A
|
WO2006002348A2
(en)
|
2004-06-23 |
2006-01-05 |
Teva Pharmaceutical Industies Ltd. |
Solid and crystalline ibandronic acid
|
EP1658275A1
(en)
|
2004-06-29 |
2006-05-24 |
Teva Pharmaceutical Industries Ltd |
Crystalline form iv of linezolid
|
CA2576307A1
(en)
|
2004-07-01 |
2006-03-09 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of 1,24(s)-dihydroxy vitamin d2
|
US7439373B2
(en)
|
2004-07-20 |
2008-10-21 |
TEVA Gyógyszergyár Zártkörúen Múködö Részvénytársaság |
Crystalline mycophenolate sodium
|
CA2575243A1
(en)
|
2004-07-22 |
2006-02-02 |
Teva Pharmaceutical Industries Ltd. |
Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation
|
US7473804B2
(en)
|
2004-07-22 |
2009-01-06 |
Teva Pharmaceutical Fine Chemicals S.R.L. |
Polymorphs of atomoxetine hydrochloride
|
KR20090120011A
(en)
|
2004-08-23 |
2009-11-23 |
테바 파마슈티컬 인더스트리즈 리미티드 |
Solid and crystalline ibandronate sodium and processes for preparation thereof
|
US20060154957A1
(en)
|
2004-09-21 |
2006-07-13 |
Nina Finkelstein |
Crystalline clopidogrel hydrobromide and processes for preparation thereof
|
WO2006037042A1
(en)
|
2004-09-28 |
2006-04-06 |
Teva Pharmaceutical Industries Ltd. |
Fexofenadine crystal form and processes for its preparation thereof
|
CA2582092A1
(en)
|
2004-11-02 |
2006-05-11 |
Teva Pharmaceutical Industries Ltd. |
Tadalafil crystal forms and processes for preparing them
|
WO2006050509A2
(en)
|
2004-11-03 |
2006-05-11 |
Teva Pharmaceutical Industries Ltd. |
Amorphous and polymorphic forms of telmisartan sodium
|
EP1812428A2
(en)
|
2004-11-19 |
2007-08-01 |
Teva Pharmaceutical Industries Ltd |
Zolmitriptan crystal forms
|
JP2007523069A
(en)
|
2004-12-01 |
2007-08-16 |
テバ ジョジセルジャール ザ−トケルエン ムケド レ−スベニュタ−ルシャシャ−グ |
Non-hygroscopic and powdered amorphous pimecrolimus
|
WO2006060808A1
(en)
|
2004-12-03 |
2006-06-08 |
Teva Pharmaceutical Industries Ltd. |
Ezetimibe polymorphs
|
DE602006009619D1
(en)
|
2005-01-11 |
2009-11-19 |
Teva Pharm Fine Chemicals Srl |
PROCESS FOR PREPARING 1-AMINO-3,5-DIMETHYLADAMANTANE HYDROCHLORIDE
|
EP1776049A2
(en)
|
2005-01-27 |
2007-04-25 |
Teva Pharmaceutical Industries Ltd. |
Duloxetine hcl polymorphs
|
US20080213404A1
(en)
|
2005-02-04 |
2008-09-04 |
Johnson Randall S |
Hif Modulating Compounds and Methods of Use Thereof
|
WO2006091656A1
(en)
|
2005-02-24 |
2006-08-31 |
Teva Pharmaceutical Industries, Ltd |
Crystals of ladostigil tartrate, methods of production and pharmaceutical compositions thereof
|
US7291614B2
(en)
|
2005-02-24 |
2007-11-06 |
Teva Pharmaceutical Industries Ltd. |
Processes for the preparation of linezolid intermediate
|
MX2007010931A
(en)
|
2005-03-08 |
2007-10-16 |
Teva Pharma |
Crystal forms of (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2- thienyl) propanamine oxalate and the preparation thereof.
|
WO2006098834A2
(en)
|
2005-03-14 |
2006-09-21 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of ziprasidone mesylate
|
WO2006108151A1
(en)
|
2005-04-06 |
2006-10-12 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of pregabalin
|
DE102005019712A1
(en)
|
2005-04-28 |
2006-11-09 |
Bayer Healthcare Ag |
Dipyridyl-dihydropyrazolone and its use
|
CN101180261A
(en)
|
2005-05-23 |
2008-05-14 |
特瓦制药工业有限公司 |
Processes for preparing cinacalcet hydrochloride crystal form i
|
AR053295A1
(en)
|
2005-05-23 |
2007-04-25 |
Cadbury Adams Usa Llc |
COMPOSITIONS THAT PROMOTE THE FLAVOR AND EDIBLE GOLOSINS AND GUM PRODUCTS THAT CONTAIN THEM
|
CN101394843A
(en)
|
2005-06-06 |
2009-03-25 |
菲布罗根公司 |
Improved treatment for anemia using a HIF-alpha stabilising agent
|
WO2006135757A1
(en)
|
2005-06-09 |
2006-12-21 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of carvedilol and processes for their preparation
|
US20070100165A1
(en)
|
2005-06-09 |
2007-05-03 |
Ronen Borochovitz |
Process for preparation of sertraline hydrochloride form I
|
WO2006138511A2
(en)
|
2005-06-15 |
2006-12-28 |
Fibrogen, Inc. |
Use of hif 1alfa modulators for treatment of cancer
|
MX2007002113A
(en)
|
2005-06-22 |
2007-04-27 |
Teva Pharma |
Polymorphic forms of tegaserod maleate.
|
US20070154482A1
(en)
|
2005-09-12 |
2007-07-05 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
WO2007038571A2
(en)
|
2005-09-26 |
2007-04-05 |
Smithkline Beecham Corporation |
Prolyl hydroxylase antagonists
|
WO2007038676A2
(en)
|
2005-09-28 |
2007-04-05 |
Teva Pharmaceutical Industries Ltd. |
Polymorphic forms of ladostigil tartrate
|
US20090176726A1
(en)
|
2005-10-11 |
2009-07-09 |
Fisher David E |
Methods for treating mitf-related disorders
|
SI1937642T1
(en)
|
2005-10-19 |
2015-01-30 |
Teva Pharmaceutical Industries Ltd. |
Crystals of laquinimod sodium, and process for the manufacture thereof
|
EP1943256A2
(en)
|
2005-10-31 |
2008-07-16 |
Teva Pharmaceutical Industries Ltd. |
Crystalline forms of cefdinir potassium salt
|
JP2008526782A
(en)
|
2005-10-31 |
2008-07-24 |
テバ ファーマシューティカル インダストリーズ リミティド |
Cefdinir cesium salt crystals
|
WO2007059307A2
(en)
|
2005-11-15 |
2007-05-24 |
Teva Pharmaceutical Industries Ltd. |
Crystalline and amorphous forms of telithromycin
|
CA2625299A1
(en)
|
2005-11-22 |
2007-05-31 |
Teva Pharmaceutical Industries Ltd. |
Crystal forms of cinacalcet hci and processes for their preparation
|
JP5202327B2
(en)
|
2005-12-09 |
2013-06-05 |
アムジエン・インコーポレーテツド |
Quinolone-based compounds exhibiting prolyl hydroxylase inhibitory activity, and compositions thereof and uses thereof
|
BRPI0610344A2
(en)
|
2005-12-13 |
2016-11-29 |
Teva Pharma |
crystallized form of atorvastatin hemi-calcium, process for its preparation, derived pharmaceutical product and its medicinal use
|
EP1968588A2
(en)
|
2006-01-05 |
2008-09-17 |
TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság |
Crystalline forms of dolasetron base and processes for preparation thereof
|
WO2007081835A2
(en)
|
2006-01-09 |
2007-07-19 |
Btg International Limited |
Modulators of hypoxia inducible factor-1 and related uses
|
EP1983823A1
(en)
|
2006-01-17 |
2008-10-29 |
VIB vzw |
Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
|
US20070208072A1
(en)
|
2006-01-18 |
2007-09-06 |
Gustavo Frenkel |
Maleate salt of tegaserod and crystalline forms thereof
|
CA2635899A1
(en)
|
2006-01-19 |
2007-07-26 |
Osi Pharmaceuticals, Inc. |
Fused heterobicyclic kinase inhibitors
|
JP4801451B2
(en)
|
2006-01-19 |
2011-10-26 |
株式会社日立ハイテクノロジーズ |
Control device and control method for electron gun used in scanning electron microscope and the like
|
ITMI20060179A1
(en)
|
2006-02-02 |
2007-08-03 |
Abiogen Pharma Spa |
PROCEDURE FOR RESOLUTION OF RACEMIC MIXTURES AND DIASTEREOISOMERIC COMPLEX OF A SOLVING AGENT AND UNANTIOMER OF INTEREST
|
MX2007012605A
(en)
|
2006-02-21 |
2008-01-11 |
Teva Pharma |
Novel crystalline forms of armodafinil and preparation thereof.
|
TW200804279A
(en)
|
2006-02-27 |
2008-01-16 |
Teva Pharma |
Fluvastatin sodium novel forms and preparation thereof
|
US7588924B2
(en)
|
2006-03-07 |
2009-09-15 |
Procter & Gamble Company |
Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
|
AR059733A1
(en)
|
2006-03-07 |
2008-04-23 |
Smithkline Beecham Corp |
COMPOSITE DERIVED FROM GLYCIN N- REPLACED WITH BICYCLE HETEROAROMATICS, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, USE TO PREPARE A MEDICINAL PRODUCT TO TREAT ANEMIA AND PROCESS FOR PREPARATION
|
WO2007109799A2
(en)
|
2006-03-23 |
2007-09-27 |
Teva Pharmaceutical Industries Ltd. |
Polymorphs of eszopiclone malate
|
WO2007136990A2
(en)
|
2006-05-16 |
2007-11-29 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
TWI394747B
(en)
|
2006-06-23 |
2013-05-01 |
Smithkline Beecham Corp |
Prolyl hydroxylase inhibitors
|
PL3026044T3
(en)
|
2006-06-26 |
2019-04-30 |
Akebia Therapeutics Inc |
Prolyl hydroxylase inhibitors and methods of use
|
TW200845994A
(en)
|
2007-01-12 |
2008-12-01 |
Smithkline Beecham Corp |
N-substituted glycine derivatives: prolyl hydroxylase inhibitors
|
CL2008000066A1
(en)
|
2007-01-12 |
2008-08-01 |
Smithkline Beecham Corp |
COMPOUNDS DERIVED FROM (5-HYDROXY-3-OXO-2,3-DIHYDROPIRIDAZINE-4-CARBONYL) GLYCINE, HIFROXYLASE HYDROXYLASE HIF INHIBITORS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE IN THE TREATMENT OF THE ANEM
|
CA2683758A1
(en)
|
2007-04-18 |
2008-10-30 |
Merck & Co., Inc. |
Novel 1,8-naphthyridine compounds
|
WO2008130508A1
(en)
|
2007-04-18 |
2008-10-30 |
Amgen Inc. |
Indanone derivatives that inhibit prolyl hydroxylase
|
EP2150251B9
(en)
|
2007-05-04 |
2013-02-27 |
Amgen, Inc |
Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
|
US8309544B2
(en)
|
2007-05-16 |
2012-11-13 |
Merck Sharp & Dohme Corp. |
Spiroindalones
|
TW200908984A
(en)
|
2007-08-07 |
2009-03-01 |
Piramal Life Sciences Ltd |
Pyridyl derivatives, their preparation and use
|
CA2696725A1
(en)
|
2007-08-10 |
2009-03-26 |
Crystalgenomics, Inc. |
Pyridine derivatives and methods of use thereof
|
WO2009039323A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
WO2009039321A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
WO2009043093A1
(en)
|
2007-10-04 |
2009-04-09 |
Newsouth Innovations Pty Limited |
Hif inhibition
|
WO2009049112A1
(en)
|
2007-10-10 |
2009-04-16 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
BRPI0820343A2
(en)
|
2007-11-08 |
2017-08-22 |
Genentech Inc |
ANTI-FACTOR B ANTIBODIES AND THEIR USES
|
WO2009067790A1
(en)
|
2007-11-26 |
2009-06-04 |
Uti Limited Partnership |
STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
|
NZ585701A
(en)
|
2007-11-30 |
2012-09-28 |
Glaxosmithkline Llc |
Benzopyrazine derivatives as prolyl hydroxylase inhibitors
|
US20100305154A1
(en)
|
2007-11-30 |
2010-12-02 |
Glaxosmithkline Llc |
Prolyl Hydroxylase Inhibitors
|
US8269008B2
(en)
|
2007-12-03 |
2012-09-18 |
Fibrogen, Inc. |
Oxazolopyridine and isoxazolopyridine derivatives for use in the treatment of HIF-mediated conditions
|
US20100298324A1
(en)
|
2007-12-19 |
2010-11-25 |
Smith Kline Beecham Corporation |
Prolyl Hydroxylase Inhibitors
|
US20110003013A1
(en)
|
2008-01-04 |
2011-01-06 |
Garvan Institute Of Medical Research |
Method of increasing metabolism
|
EP2252619B1
(en)
|
2008-01-11 |
2013-10-09 |
Fibrogen, Inc. |
Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
|
AR071997A1
(en)
|
2008-06-04 |
2010-07-28 |
Bristol Myers Squibb Co |
CRYSTAL FORM OF 6 - ((4S) -2-METHYL-4- (2-NAFTIL) -1,2,3,4-TETRAHYDROISOQUINOLIN-7-IL) PIRIDAZIN-3-AMINA
|
NO2686520T3
(en)
|
2011-06-06 |
2018-03-17 |
|
|
JP2014522410A
(en)
|
2011-06-06 |
2014-09-04 |
アケビア セラピューティクス インコーポレイテッド |
Compounds and compositions for stabilizing hypoxia-inducible factor-2α as a method for cancer treatment
|
JP6099644B2
(en)
|
2011-07-22 |
2017-03-22 |
ベイジン ベータ ファーマシューティカルズ カンパニー, リミテッド |
Polymorphs of compounds as prolyl hydroxylase inhibitors and uses thereof
|
US8772895B2
(en)
|
2011-11-28 |
2014-07-08 |
Taiwan Semiconductor Manufacturing Company, Ltd. |
Dark current reduction for back side illuminated image sensor
|
EP2637274B1
(en)
|
2012-03-05 |
2022-05-04 |
Vetco Gray Scandinavia AS |
Power cable termination arrangement
|
DK3007695T3
(en)
|
2013-06-13 |
2024-03-18 |
Akebia Therapeutics Inc |
COMPOSITIONS AND METHODS FOR THE TREATMENT OF ANEMIA
|
JP2016537365A
(en)
|
2013-11-15 |
2016-12-01 |
アケビア セラピューティクス インコーポレイテッドAkebia Therapeutics Inc. |
{[5- (3-Chlorophenyl) -3-hydroxypyridine-2-carbonyl] amino} acetic acid solid form, composition and use thereof
|
US20160339005A1
(en)
|
2014-01-23 |
2016-11-24 |
Akebia Therapeutics, Inc. |
Compositions and methods for treating ocular diseases
|
BR112017015852A2
(en)
|
2015-01-23 |
2018-03-27 |
Akebia Therapeutics Inc |
crystal form, hemichalic salt, hemicalic salt dihydrate, hydrous monosodium salt, monohydrate bisodium salt, anhydrous monosodium salt and method for preparing compound 1
|
EP3270922A4
(en)
|
2015-03-20 |
2018-08-01 |
Akebia Therapeutics Inc. |
Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
|
HRP20211862T1
(en)
|
2015-04-01 |
2022-03-04 |
Akebia Therapeutics, Inc. |
Compositions and methods for treating anemia
|
EP3763703A3
(en)
|
2016-12-13 |
2021-03-03 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
Novel crystalline forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid and processes for preparation thereof
|
AR114886A1
(en)
|
2018-05-09 |
2020-10-28 |
Akebia Therapeutics Inc |
PROCESS TO PREPARE 2 - [[5- (3-CHLOROPHENYL) -3-HYDROXYPYRIDIN-2-CARBONYL] AMINO] ACETIC ACID
|
MX2022005104A
(en)
|
2019-10-31 |
2022-07-21 |
Akebia Therapeutics Inc |
Therapeutic methods using vadadustat.
|
US11524939B2
(en)
|
2019-11-13 |
2022-12-13 |
Akebia Therapeutics, Inc. |
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
|